Skip to content
    IC

    Intermediate Capital Group

    Intermediate Capital Group is a Series A to Series C stage investment firm. It has made 4 investments. Their most common stage is series-c (40% of deals). Average disclosed round size is $107.8M (across 5 rounds with reported amounts).

    Find people at Intermediate Capital Group on Goldilocks AI

    Portfolio

    4

    Fund Size

    —

    Top Stage

    Series C

    Last 12 Mo

    0

    Team

    AT

    Adam T. Goodman

    Managing Director

    BC

    Bernard Coady

    Managing Director

    JR

    Jamie Rivers

    Managing Director

    JR

    Jeffrey Rabel

    Managing Director

    JM

    Justin McDougall

    Managing Director

    LL

    Luca Lelli

    Managing Director

    AH

    Azeem Haider

    Principal

    DM

    David Malton

    Principal

    LM

    Liam McGivern

    European Mid-Market Private Equity Investor

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    5 investments
    CompanyRoundAmountDate
    AAmolyt PharmaSeries C$130MJan 2023
    Amolyt Pharma logoAmolyt PharmaSeries C$138MJan 2023
    EEliem TherapeuticsSeries B$60MMay 2021
    WWugenSeries B$172MJan 2021
    EEliem TherapeuticsSeries A$39M—

    Top Co-Investors

    Andera Partners2 shared
    Pontifax2 shared
    EQT Life Sciences2 shared
    Mass General Brigham Ventures2 shared
    OrbiMed2 shared
    Sofinnova Partners2 shared
    Sectoral Asset Management2 shared
    ICG plc2 shared
    Novo Capital2 shared
    Kurma Partners2 shared
    RA Capital Management2 shared
    UI Investissement1 shared
    Falcon Edge1 shared
    RiverVest Venture Partners1 shared
    Fidelity Management & Research Company1 shared
    Alexandria Venture Investments1 shared
    LYZZ Capital1 shared
    Sands Capital1 shared
    Abingworth LLP1 shared
    Alpha Wave Incubation1 shared

    Last updated: 19 September 2026